He Feng, Xia Zhongjiang, Wang Hui, Zhu Jinjun, Hu Laiwen
Department of Infectious Diseases, Anqing First People's Hospital Affiliated to Anhui Medical University, Anqing City, Anhui Province 246000, China.
Evid Based Complement Alternat Med. 2022 Jun 21;2022:1673453. doi: 10.1155/2022/1673453. eCollection 2022.
The negative rate of serum HBV DNA, HBeAg, and ALT in the tenofovir group was significantly higher than that in the entecavir group (86.67%, 3.33%, and 80.00%) (all < 0.05). In the tenofovir group, 2cases were considered. . The aim of this study is to analyze the clinical effect and safety of tenofovir in the treatment of chronic hepatitis B (CHB) patients. . A total of 60 patients with CHB who were admitted and treated in Anqing First People's Hospital Affiliated to Anhui Medical University from January 2019 to July 2020 were randomly assigned at a ratio of 1 : 1 into the tenofovir group (treated with tenofovir) and the entecavir group (treated with entecavir) via the random number table method. The clinical therapeutic effect and safety of the two groups were compared. . The serum hepatitis B virus (HBV) DNA levels in the two groups decreased after treatment, but there was no significant difference. Ths (2.50%) had nausea, 1 (1.25%) had headache, and 0 had an elevated creatine kinase. In the tenofovir group,1(3.33%) had nausea, 0 had headache, and 0 had an elevated creatine kinase. In the entecavir group, there were 3 (10.00%) cases of nausea, 2 (6.67%) cases of headache, and 1 (3.33%) case of elevated creatine kinase. The overall incidence of adverse reactions in the tenofovir group (3.33%) was significantly lower than that in the entecavir group (20.00%) (all < 0.05). . Tenofovir is more effective than entecavir in the treatment of patients with CHB due to low incidence of adverse events and a good safety profile.
替诺福韦组血清HBV DNA、HBeAg及ALT的阴性率显著高于恩替卡韦组（分别为86.67%、3.33%和80.00%）（均P<0.05）。在替诺福韦组，有2例被考虑……本研究旨在分析替诺福韦治疗慢性乙型肝炎（CHB）患者的临床疗效及安全性……2019年1月至2020年7月在安徽医科大学附属安庆市第一人民医院收治并治疗的60例CHB患者，通过随机数字表法按1∶1比例随机分为替诺福韦组（接受替诺福韦治疗）和恩替卡韦组（接受恩替卡韦治疗）。比较两组的临床治疗效果及安全性……两组治疗后血清乙型肝炎病毒（HBV）DNA水平均下降，但差异无统计学意义。替诺福韦组有2例（2.50%）出现恶心，1例（1.25%）出现头痛，0例肌酸激酶升高。恩替卡韦组有1例（3.33%）出现恶心，0例出现头痛，0例肌酸激酶升高。恩替卡韦组有3例（10.00%）出现恶心，2例（6.67%）出现头痛，1例（3.33%）肌酸激酶升高。替诺福韦组不良反应总发生率（3.33%）显著低于恩替卡韦组（20.00%）（均P<0.05）……替诺福韦治疗CHB患者比恩替卡韦更有效，因为不良事件发生率低且安全性良好。
